medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-30-43-47medalphabet-2297Research ArticleСОВРЕМЕННАЯ ЛАБОРАТОРИЯMODERN LABORATORYКлинико‑лабораторные маркеры кальцифицирующего атеросклерозаClinical and laboratory markers of calcifying atherosclerosishttps://orcid.org/0000-0001-6735-3757ДрыгинаЛ. Б.DryginaL. B.

Дрыгина Лариса Борисовна, д. б. н., проф., вед. н. с. научно-исследовательского отдела

Санкт-Петербург

Drygina Larisa B., Dr. Bio Sci.(habil.), professor, lead researcher at Research Dept

Saint Petersburg

grygina@arcerm.spb.ruХирмановВ. Н.KhirmanovV. N.

Хирманов Владимир Николаевич, д. м. н., проф., зав. отделения сердечно-сосудистой патологии

Санкт-Петербург

Khirmanov Vladimir N., DM Sci (habil.), professor, head of Dept of Cardiovascular Diseases

Saint Petersburg

vkhirmanov@mail.ruФГБУ «Всероссийский центр экстренной и радиационной медицины имени А. М. Никифорова» МЧС РоссииРоссияAll-Russian Centre for Emergency and Radiation Medicine n. a. A. M. NikiforovRussian Federation202101122021130Современная лаборатория (2)4347Copyright © Дрыгина Л.Б., Хирманов В.Н., 20212021Дрыгина Л.Б., Хирманов В.Н.Drygina L.B., Khirmanov V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2297

Несмотря на достижения в области выявления отложения кальция в стенках сосудов, данные о взаимосвязи кальциноза коронарных артерий с клинико-лабораторными показателями кальцификации в крови практически отсутствуют, а механизмы этого процесса полностью не установлены. Цель работы заключалась в установлении взаимосвязи между показателями выраженности кальциноза сосудов и клинико-лабораторными маркерами сосудистой кальцификации для повышения эффективности диагностики заболеваний сердечно-сосудистой системы и оптимизации терапии. Полученные в ходе исследования данные свидетельствуют о высокой распространенности кальциноза сосудов у больных атеросклерозом. Оценки кальциевого индекса и традиционных факторов риска не всегда бывает достаточно для прогнозирования сердечно-сосудистых осложнений. Таким образом, выделение специфических лабораторных маркеров кальцификации и предрасположенности к кальцинозу является весьма актуальным в настоящее время. В проведенных исследованиях показано, что атеросклероз с кальцинозом сосудов сочетается с развитием хронического системного воспаления и воспаления сосудистой стенки. При этом отмечаются повышенные уровни С-реактивного белка, эндотелина, гомоцистеина, показателей липидного обмена и сниженные уровни фетуина-А в крови, что позволяет рекомендовать эти лабораторные показатели для предотвращения сердечно-сосудистых осложнений.

Despite the achievements in the detection of calcium deposits in the walls of blood vessels, there is practically no data on the relationship of calcification of the coronary arteries with clinical and laboratory indicators of calcification in the blood, and the mechanisms of this process have not been fully established. The aim of the work was to establish the relationship between the severity of vascular calcification and clinical and laboratory markers of vascular calcification to improve the effectiveness of the diagnosis of diseases of the cardiovascular system and optimize therapy. The data obtained during the study indicate a high prevalence of vascular calcification in patients with atherosclerosis. Estimates of the calcium index and traditional risk factors are not always sufficient to predict cardiovascular complications. Thus, the identification of specific laboratory markers of calcification and predisposition to calcinosis is very relevant at the present time. Studies have shown that atherosclerosis with vascular calcification is combined with the development of chronic systemic inflammation and inflammation of the vascular wall. At the same time, there are elevated levels of C-reactive protein, endothelin, homocysteine, lipid metabolism indicators, and reduced levels of fetuin-A in the blood, which allows us to recommend these laboratory indicators to prevent cardiovascular complications.

кальциевый индекскальциноз коронарных артерийбиомаркеры кальцинозаcalcium indexcalcifcation of coronary arteriesbiomarkers of calcifcatReferencesНаумов А. В. Гомоцистеин в патогенезе микроциркуляторных и тромботических осложнений. А. В. Наумов, Т. Н. Гриневич, В. М. Найдина. Тромбоз гемостаз и реология. 2012. № 1. С. 9–19.A.V. Naumov Homocysteine in the pathogenesis of microcirculatory and thrombotic complications. A. V. Naumov, T. N. Grinevich, V. M. Naidin. Thrombosis, hemostasis and rheology. 2012. No. 1. P. 9–19.A1C and Coronary Artery Calcifcation in Nondiabetic Men and Women. Y. Chang, K.E. Yun, H. Jung, C. Kim et al. Arteriosclerosis Thrombosis and Vascular Biology. 2013.A1C and Coronary Artery Calcifcation in Nondiabetic Men and Women. Y. Chang, K.E. Yun, H. Jung, C. Kim et al. Arteriosclerosis Thrombosis and Vascular Biology. 2013.Bayne Selby Jr.J. Coronary Artery Calcifcation on CT Scanning. J. Bayne Selby Jr., P. Bowe Morris. Электронный ресурс: Medscape Reference, 2013. reference.medscape.com.Bayne Selby Jr.J. Coronary Artery Calcifcation on CT Scanning. J. Bayne Selby Jr., P. Bowe Morris. Электронный ресурс: Medscape Reference, 2013. reference.medscape.com.Chow A.L.S. Coronary CT Angiography guided medical therapy in subclinical atherosclerosis. Alyssa L.S. Chow, S.D. Alhassani, A.M. Crean, G.R. Small. J. Clin. Med. 2021. Feb. 7, 10 (4). Epreb.Chow A.L.S. Coronary CT Angiography guided medical therapy in subclinical atherosclerosis. Alyssa L.S. Chow, S.D. Alhassani, A.M. Crean, G.R. Small. J. Clin. Med. 2021. Feb. 7, 10 (4). Epreb.Demer L. The Roles of Lipid Oxidation Products and Receptor Activator of Nuclear Factor-kB Signaling in Atherosclerotic Calcifcation. L. Demer, Y. Tintut. Circ. Res. 2011. Vol. 108. P. 1482–1493.Demer L. The Roles of Lipid Oxidation Products and Receptor Activator of Nuclear Factor-kB Signaling in Atherosclerotic Calcifcation. L. Demer, Y. Tintut. Circ. Res. 2011. Vol. 108. P. 1482–1493.Graham I. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. I. Graham, D. Atar, K. Borch-Johnsen et al. Eur. Heart. J. 2007. Vol. 28. P. 2375–2414.Graham I. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. I. Graham, D. Atar, K. Borch-Johnsen et al. Eur. Heart. J. 2007. Vol. 28. P. 2375–2414.Hartiala O. Adolescence risk factors are predictive of coronary artery calcifcation at middle age: the cardiovascular risk in young Finns study. O. Hartiala, C.G. Magnussen, S. Kajander, J. Knuuti. J. Am. Coll. Cardiol. 2012. Vol. 60, (15). P. 1364–1370.Hartiala O. Adolescence risk factors are predictive of coronary artery calcifcation at middle age: the cardiovascular risk in young Finns study. O. Hartiala, C.G. Magnussen, S. Kajander, J. Knuuti. J. Am. Coll. Cardiol. 2012. Vol. 60, (15). P. 1364–1370.Jahnen-Dechent W. Fetuin-A Regulation of Calcifed Matrix Metabolism. W. Jahnen-Dechent, A. Heiss, C. Schafer, M. Ketteler. Circ. Res. 2011. Vol. 108. P. 1494–1509.Jahnen-Dechent W. Fetuin-A Regulation of Calcifed Matrix Metabolism. W. Jahnen-Dechent, A. Heiss, C. Schafer, M. Ketteler. Circ. Res. 2011. Vol. 108. P. 1494–1509.Miller J. D. Calcifc Aortic Valve Stenosis: Methods, Models, and Mechanisms. J.D. Miller, R.M. Weiss, D.D. Heistad. Circ. Res. 2011. Vol. 108 (11). P. 1392–1412.Miller J. D. Calcifc Aortic Valve Stenosis: Methods, Models, and Mechanisms. J.D. Miller, R.M. Weiss, D.D. Heistad. Circ. Res. 2011. Vol. 108 (11). P. 1392–1412.New S.E.P. Molecular Imaging Insights into Early Inflammatory Stages of Arterial and Aortic Valve Calcifcation. S.E.P. New. E. Aikawa. Circulation Research. 2011. Vol. 108. P. 1381–1391.New S.E.P. Molecular Imaging Insights into Early Inflammatory Stages of Arterial and Aortic Valve Calcifcation. S.E.P. New. E. Aikawa. Circulation Research. 2011. Vol. 108. P. 1381–1391.Patel J. Inflammation and Coronary Artery Calcifcation in South Asians: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study. J. Patel, M. Al. Rifai, C. Ayers et al. Circulation. 2016. Vol. 134. Р. 17316.Patel J. Inflammation and Coronary Artery Calcifcation in South Asians: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study. J. Patel, M. Al. Rifai, C. Ayers et al. Circulation. 2016. Vol. 134. Р. 17316.Pearson T.A. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. T.A. Pearson, G.A. Mensah, R.W. et al. Circulation.2003. Vol. 107. P. 499–511.Pearson T.A. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. T.A. Pearson, G.A. Mensah, R.W. et al. Circulation.2003. Vol. 107. P. 499–511.Rosenfeld M. E. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. M.E. Rosenfeld, L.A. Campbell. Thromb. Haemost. 2011. Vol. 106 (5). P. 858–867.Rosenfeld M. E. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. M.E. Rosenfeld, L.A. Campbell. Thromb. Haemost. 2011. Vol. 106 (5). P. 858–867.Rutecki G.W. Novel Risk Factors Improve Prediction of Cardiovascular Disease in Intermediate-Risk Persons. G.W. Rutecki. электронный ресурс: 2012. www.consultantlive.com.Rutecki G.W. Novel Risk Factors Improve Prediction of Cardiovascular Disease in Intermediate-Risk Persons. G.W. Rutecki. электронный ресурс: 2012. www.consultantlive.com.Schafer C. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcifcation. C. Schafer, A. Heiss, A. Schwarz, R. Westenfeld et al. The Journal of Clinical Investigation. 2003. Vol. 112 (3). P. 357–366.Schafer C. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcifcation. C. Schafer, A. Heiss, A. Schwarz, R. Westenfeld et al. The Journal of Clinical Investigation. 2003. Vol. 112 (3). P. 357–366.Schinke T. Vascular calcifcation – a passive process in need of inhibitors. S. Thorsten, G. Karsenty. Nephrol. Dial. Transplant. 2000. Vol. 15 (9). P. 1272–1274.Schinke T. Vascular calcifcation – a passive process in need of inhibitors. S. Thorsten, G. Karsenty. Nephrol. Dial. Transplant. 2000. Vol. 15 (9). P. 1272–1274.Shaw L.J. An Approach to Asymptomatic and Atypically or Typically Symptomatic Women with Cardiac Disease. L.J. Shaw. Interventional Cardiology Clinics. 2012. Vol. 1, Issue 2. P. 157–163; C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. The Emerging Risk Factors Collaboration. N. Engl. J. Med. 2012. Vol. 367. P. 1310–1320.Shaw L.J. An Approach to Asymptomatic and Atypically or Typically Symptomatic Women with Cardiac Disease. L.J. Shaw. Interventional Cardiology Clinics. 2012. Vol. 1, Issue 2. P. 157–163; C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. The Emerging Risk Factors Collaboration. N. Engl. J. Med. 2012. Vol. 367. P. 1310–1320.Towler D.A. Thematic Series on the Pathobiology of Vascular Calcifcation an Introduction. D.A. Towler, L.L. Demer. Circ. Res. 2011. Vol. 108. P. 1378–1380.Towler D.A. Thematic Series on the Pathobiology of Vascular Calcifcation an Introduction. D.A. Towler, L.L. Demer. Circ. Res. 2011. Vol. 108. P. 1378–1380.Wang J. Common genetic variants of MGP are associated with calcifcation on the arterial wall but not with calcifcation present in the atherosclerotic plaques. Y. Wang, J. Chen, Y. Zhang, W. Yu, C. Zhang, L. Gong, L. Shao, J. Lu, Y. Gao, X. Chen, X. Chen, R. Hui. Circ. Cardiovasc. Genet. 2013. Vol. 6 (3). P. 271–278.Wang J. Common genetic variants of MGP are associated with calcifcation on the arterial wall but not with calcifcation present in the atherosclerotic plaques. Y. Wang, J. Chen, Y. Zhang, W. Yu, C. Zhang, L. Gong, L. Shao, J. Lu, Y. Gao, X. Chen, X. Chen, R. Hui. Circ. Cardiovasc. Genet. 2013. Vol. 6 (3). P. 271–278.WHO updates: Cardiovascular risk. The world health report, 2019. Электронный ресурс: http://Cardiovascular diseases/www.who.int.WHO updates: Cardiovascular risk. The world health report, 2019. Электронный ресурс: http://Cardiovascular diseases/www.who.int.

The authors declare that there are no conflicts of interest present.